Yuk-Fun Liu

Yuk-Fun Liu

Auto-generated profile, based on publicly available information

Yuk-Fun Liu

Department of Diabetes and Endocrinology Guy's and St Thomas' NHS Foundation Trust London UK

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 August 2017 in Science Translational Medicine
Verified
Journal Article
Closed access
PDF file
MAMohammad Alhadj Ali
Mohammad Alhadj Ali
YLYuk-Fun Liu
Yuk-Fun Liu
SASefina Arif
Sefina Arif
DTDanijela Tatovic
Danijela Tatovic
HSHina Shariff
Hina Shariff
CDColin M. Dayan
Colin M. Dayan
Immunotherapy using short immunogenic peptides of disease-related autoantigens restores immune tolerance in preclinical disease models. We studied safety and mechanistic effects of injecting human leukocyte antigen–DR4(DRB1*0401)–restricted immunodominant proinsulin peptide intradermally every 2 or 4 weeks for 6 months in newly diagnosed type 1 diabetes patients. Treatment was well tolerated with no systemic or local hypersensitivity. Placebo subjects showed a significant decline in stimulated C-peptide (measuring insulin reserve) at 3, 6, 9, and 12 months versus baseline, whereas no significant change was seen in the 4-weekly peptide group at these time points or the 2-weekly group at 3, 6, and 9 months. The placebo group’s daily insulin use increased by 50% over 12 months but remained unchanged in the intervention groups. C-peptide retention in treated subjects was associated with proinsulin-stimulated interleukin-10 production, increased FoxP3 expression by regulatory T cells, low baseline levels of activated β cell–specific CD8 T cells, and favorable β cell stress markers (proinsulin/C-peptide ratio). Thus, proinsulin peptide immunotherapy is safe, does not accelerate decline in β cell function, and is associated with antigen-specific and nonspecific immune modulation.

15 February 2017 in Diabetes Care
Verified
Journal Article
Open access
PDF file
CFChristine Therese Ferrara
Christine Therese Ferrara
SGSusan Michelle Geyer
Susan Michelle Geyer
YLYuk-Fun Liu
Yuk-Fun Liu
CECarmella Evans-Molina
Carmella Evans-Molina
ILIngrid M. Libman
Ingrid M. Libman
TGthe Type 1 Diabetes TrialNet Study Group
the Type 1 Diabetes TrialNet Study Group
OBJECTIVE: We aimed to determine the effect of elevated BMI over time on the progression to type 1 diabetes in youth. RESEARCH DESIGN AND METHODS: We studied 1,117 children in the TrialNet Pathway to Prevention cohort (autoantibody-positive relatives of patients with type 1 diabetes). Longitudinally accumulated BMI above the 85th age- and sex-adjusted percentile generated a cumulative excess BMI (ceBMI) index. Recursive partitioning and multivariate analyses yielded sex- and age-specific ceBMI thresholds for greatest type 1 diabetes risk. RESULTS: Higher ceBMI conferred significantly greater risk of progressing to type 1 diabetes. The increased diabetes risk occurred at lower ceBMI values in children <12 years of age compared with older subjects and in females versus males. CONCLUSIONS: Elevated BMI is associated with increased risk of diabetes progression in pediatric autoantibody-positive relatives, but the effect varies by sex and age.

22 February 2017 in Diabetic Medicine
Verified
Journal Article
Closed access
PDF file
YLY. Liu
Y. Liu
LRL. E. Rafkin
L. E. Rafkin
DMD. Matheson
D. Matheson
CHC. Henderson
C. Henderson
DBD. Boulware
D. Boulware
TGthe Type 1 Diabetes TrialNet Study Group
the Type 1 Diabetes TrialNet Study Group

24 November 2017 in Pediatric Diabetes
Verified
Journal Article
Closed access
PDF file
JSJay M Sosenko
Jay M Sosenko
SGSusan Geyer
Susan Geyer
JSJay S Skyler
Jay S Skyler
LRLisa E Rafkin
Lisa E Rafkin
HIHeba M Ismail
Heba M Ismail
JPJerry P Palmer
Jerry P Palmer

1 December 2013 in The Journal of Immunology
Verified
Journal Article
Closed access
MEMegan Estorninho
Megan Estorninho
VGVivienne B Gibson
Vivienne B Gibson
DKDeborah Kronenberg-Versteeg
Deborah Kronenberg-Versteeg
YLYuk-Fun Liu
Yuk-Fun Liu
CNChester Ni
Chester Ni
MPMark Peakman
Mark Peakman
Extensive diversity in the human repertoire of TCRs for Ag is both a cornerstone of effective adaptive immunity that enables host protection against a multiplicity of pathogens and a weakness that gives rise to potential pathological self-reactivity. The complexity arising from diversity makes detection and tracking of single Ag-specific CD4 T cells (ASTs) involved in these immune responses challenging. We report a tandem, multistep process to quantify rare TCRβ-chain variable sequences of ASTs in large polyclonal populations. The approach combines deep high-throughput sequencing (HTS) within functional CD4 T cell compartments, such as naive/memory cells, with shallow, multiple identifier–based HTS of ASTs identified by activation marker upregulation after short-term Ag stimulation in vitro. We find that clonotypes recognizing HLA class II–restricted epitopes of both pathogen-derived Ags and self-Ags are oligoclonal and typically private. Clonotype tracking within an individual reveals private AST clonotypes resident in the memory population, as would be expected, representing clonal expansions (identical nucleotide sequence; “ultraprivate”). Other AST clonotypes share CDR3β amino acid sequences through convergent recombination and are found in memory populations of multiple individuals. Tandem HTS-based clonotyping will facilitate studying AST dynamics, epitope spreading, and repertoire changes that arise postvaccination and following Ag-specific immunotherapies for cancer and autoimmune disease.

1 June 2004 in British Journal of Dermatology
Verified
Journal Article
Closed access
PDF file
CLC-Y. Li
C-Y. Li
TGT-W. Gao
T-W. Gao
GWGang Wang
Gang Wang
ZHZ-Y. Han
Z-Y. Han
ZSZHU SHEN
ZHU SHEN
YLY-F. Liu
Y-F. Liu